



Participant name:

Hospital ID:

CHI/Date of Birth:

**SOPHIST - SOTagliflozin in Patients with Heart failure Symptoms and Type 1 Diabetes**

Sponsor University of Dundee-NHS Tayside  
 Chief Investigator Dr Ify Mordi  
 IRAS number 1007807

Principal Investigator

Contact number

Contact email

**Visit 4**

Date of visit:  Participant trial ID

Please tick to indicate the following have been completed:

Confirmed participant's identity	<input type="checkbox"/>
Participant has verbally given their consent to continue in the trial	<input type="checkbox"/>
Concomitant medications have been reviewed	<input type="checkbox"/>
Adverse events have been reviewed	<input type="checkbox"/>
Education/review of glucose and ketone management undertaken including hypoglycaemic and DKA events, glucose/ketone readings, and insulin doses	<input type="checkbox"/>
Participant compliance with treatment	<input type="checkbox"/>

The following must be filed in the participant's medical notes:

- Changes to concomitant medications since last visit
- Any adverse events since last visit
- Details of review of diabetes management including any changes to insulin or other diabetes medication
- Any hypoglycaemic and DKA events since last visit
- Any other notable findings and actions taken
- If the participant was withdrawn from the trial at this visit, document reason

Any further information of note:



Participant name:

Hospital ID:

CHI/Date of Birth:


Visit has been carried out as per protocol

Signature:

Name:

Job title:

Date:
